Anebulo Pharmaceuticals, Inc. (ANEB)
OTCMKTS · Delayed Price · Currency is USD
0.4340
+0.0740 (20.56%)
Mar 2, 2026, 4:00 PM EST
Anebulo Pharmaceuticals Company Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States.
The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity.
Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Anebulo Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Richard Cunningham |
Contact Details
Address: 1017 Ranch Road 620 South Lakeway, Texas 78734 United States | |
| Phone | 512 598 0931 |
| Website | anebulo.com |
Stock Details
| Ticker Symbol | ANEB |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| ISIN Number | US0345691036 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard Anthony Cunningham | Chief Executive Officer and Director |
| Dr. Joseph F. Lawler M.D., Ph.D. | Founder and Chairman |
| Daniel V. George | Acting Chief Financial Officer and Secretary |
| Dr. Kenneth C. Cundy Ph.D. | Chief Scientific Officer |